|Bid||16.91 x 1100|
|Ask||16.94 x 1800|
|Day's Range||15.86 - 16.96|
|52 Week Range||1.92 - 33.79|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.00|
Inovio Pharmaceuticals (NASDAQ: INO) has been one of 2020's hottest coronavirus vaccine stocks. At one point, it was trading 10 times higher than it began the year, due largely to the speed at which it moved its COVID-19 vaccine candidate through the development process and into phase 1 clinical trials. Now, Inovio shares are nowhere near the peak they hit in June, and the stock appears to be sliding yet again as the broader market withdraws from its summer highs.
During Q2, Inovio Pharmaceuticals's (NASDAQ: INO) reported sales totaled $267.19 thousand. Despite a 15.17% in earnings, the company posted a loss of $29.06 million. In Q1, Inovio Pharmaceuticals brought in $1.33 million in sales but lost $25.23 million in earnings.What Is ROCE? Changes in earnings and sales indicate shifts in Inovio Pharmaceuticals's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, Inovio Pharmaceuticals posted an ROCE of -0.16%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.View more earnings on INOReturn on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.In Inovio Pharmaceuticals's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.Q2 Earnings Recap Inovio Pharmaceuticals reported Q2 earnings per share at $-0.2/share, which did not meet analyst predictions of $-0.17/share.See more from Benzinga * Unusual Options Activity Insight: Inovio Pharmaceuticals * ROCE Insights For Inovio Pharmaceuticals * Unusual Options Activity Insight: Inovio Pharmaceuticals(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The U.S. is inching closer to hitting 7 million coronavirus cases as Midwest states like Wisconsin, Montana and South Dakota see an uptick. This comes as big pharmaceutical companies race to find a vaccine. Yahoo Finance's Anjalee Khemlani joins The First Trade with Alexis Christoforous and Brian Sozzi to discuss that and what pharmaceutical companies are close to reaching final stages of coronavirus vaccine trials.